{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  "substanceId": "5meo_dmt_001",
  
  "substance": {
    "id": "5meo_dmt_001",
    "name": "5-MeO-DMT",
    "fullName": "5-Methoxy-N,N-dimethyltryptamine",
    "aliases": ["5-MeO", "The Toad", "Bufo"],
    "classification": {
      "primary": "atypical_psychedelic",
      "secondary": ["tryptamine", "non_selective_serotonin_agonist"],
      "mechanism": "Non-selective serotonin receptor agonist",
      "receptorAffinity": {
        "5HT1A": "very_high",
        "5HT2A": "moderate_to_high",
        "distinctionNote": "Higher affinity for 5-HT1A than 5-HT2A, unlike typical psychedelics"
      },
      "comparisonToClassical": "Different mechanism and subjective profile than classical psychedelics"
    },
    "naturalSources": [
      {
        "source": "Incilius alvarius",
        "commonName": "Sonoran Desert toad",
        "component": "venom",
        "concentration": "high",
        "variability": "significant",
        "additionalCompounds": ["bufotenine", "other_compounds"],
        "ethicalConcerns": ["animal_welfare", "population_impact"]
      },
      {
        "source": "various_plants",
        "examples": ["Anadenanthera peregrina (yopo)", "Virola theiodora"],
        "variability": "high"
      },
      {
        "source": "fungi",
        "specificity": "various_species",
        "concentration": "variable"
      }
    ],
    "syntheticProduction": {
      "available": true,
      "advantages": ["Consistent potency", "No animal harm", "Purity control"],
      "risks": ["Impurities from synthesis", "Potential mislabeling"]
    },
    "prevalenceData": {
      "lifetimeUse": [
        {
          "value": 1.2,
          "unit": "percent",
          "population": "US adults",
          "timeframe": "2009-2013",
          "substanceGroup": "psychedelic tryptamines (including DMT and 5-MeO-DMT)",
          "citations": ["lancelotta_2020"]
        }
      ],
      "demographics": {
        "primaryUsers": "Caucasian males with history of other substance use",
        "citations": ["lancelotta_2020"]
      },
      "usePatterns": {
        "frequency": "Infrequent - most report once a year or less",
        "primaryMotivation": "Spiritual exploration",
        "therapeuticUse": "Improving PTSD, depression, anxiety, addiction symptoms",
        "citations": ["davis_2018"]
      },
      "globalData": {
        "availability": "limited",
        "reason": "Not typically included in epidemiological surveys",
        "grouping": "Often grouped with other tryptamines and synthetic cathinones",
        "citations": ["davis_2018"]
      },
      "needForCare": {
        "association": "Strongest association with perceived need for care among psychedelics",
        "reason": "Elevated risk of contraindications",
        "citations": ["engel_2024"]
      }
    },
    "legalStatus": {
      "international": "Schedule I (USA) and controlled in many countries",
      "variability": "Legal status varies by jurisdiction"
    }
  },

  "subjectiveEffects": {
    "generalCharacteristics": {
      "intensity": "More intense than other psychedelics",
      "uniqueness": "Distinctly different from classical psychedelics",
      "unpredictability": "Highly variable between individuals",
      "citations": ["dourron_2023", "rucker_2024"]
    },
    "coreExperiences": [
      {
        "effect": "ego_dissolution",
        "intensity": "profound",
        "frequency": "very_common",
        "description": "Complete loss of sense of self"
      },
      {
        "effect": "mystical_type_experiences",
        "comparability": "Comparable to psilocybin in some contexts",
        "citations": ["dourron_2023", "rucker_2023"]
      },
      {
        "effect": "peak_experiences",
        "intensity": "profound",
        "description": "Intense transcendent experiences"
      },
      {
        "effect": "loss_of_control",
        "frequency": "common",
        "intensity": "profound"
      },
      {
        "effect": "nothingness_whiteout",
        "description": "Experience of void or complete absence",
        "uniqueness": "More common with 5-MeO-DMT than other psychedelics",
        "mayInclude": ["subjective_void", "amnesia_of_experience"],
        "citations": ["dourron_2023"]
      },
      {
        "effect": "death_experience",
        "description": "Feeling of being dead or dying",
        "frequency": "reported_by_some",
        "intensity": "profound",
        "citations": ["lancelotta_2020"]
      }
    ],
    "comparisonToOtherPsychedelics": {
      "intensity": "Described as 'more intense'",
      "visualCharacter": "Less visual than DMT, more void-like",
      "duration": "Shorter than most psychedelics",
      "mysticalQualities": "Can induce mystical experiences comparable to psilocybin",
      "citations": ["dourron_2023", "rucker_2023"]
    },
    "firstTimeUserData": {
      "challengingEffects": {
        "prevalence": 37,
        "unit": "percent",
        "effects": [
          "heart_beating",
          "fear",
          "body_shaking",
          "anxiety",
          "feeling_like_dying",
          "pressure_on_chest",
          "panic"
        ],
        "citations": ["lancelotta_2020"]
      }
    }
  },

  "dosing": {
    "researchLimitations": {
      "note": "Less data available than other psychedelics",
      "humanDoseStudies": "Not extensively conducted in volunteers",
      "uncertainty": "Difficult to define safe dosage ranges",
      "citations": ["engel_2024"]
    },
    "clinicalDoses": {
      "intranasal": {
        "min": 1,
        "max": 12,
        "unit": "mg",
        "doseResponseObserved": true,
        "note": "Subjective effects and intensity increase with dose",
        "citations": ["rucker_2023"]
      }
    },
    "recreationalDoses": {
      "inhaled": {
        "min": 6,
        "max": 20,
        "unit": "mg",
        "citations": ["engel_2024"]
      },
      "intravenous": {
        "min": 0.7,
        "max": 3.1,
        "unit": "mg",
        "citations": ["engel_2024"]
      }
    },
    "doseResponseCurve": {
      "characteristic": "steep",
      "implication": "Small dose increases can cause large effect increases",
      "riskImplication": "Increases risk for users",
      "citations": ["lancelotta_2020"]
    },
    "uncertaintyFactors": [
      "Variable user knowledge of dose consumed",
      "Difficulty measuring precise amounts",
      "Source variability (toad vs synthetic)",
      "Lack of standardization"
    ],
    "weightDependence": "Not well characterized"
  },

  "pharmacokinetics": {
    "routeDependent": {
      "variability": "Significant differences by route",
      "impact": "Affects onset, intensity, and duration",
      "citations": ["rucker_2024"]
    },
    "inhalation": {
      "onset": {
        "time": "seconds to 1 minute",
        "speed": "very_rapid"
      },
      "peak": {
        "time": {"min": 2, "max": 5, "unit": "minutes"}
      },
      "duration": {
        "time": {"min": 15, "max": 20, "unit": "minutes"}
      },
      "intensity": "very_high",
      "citations": ["engel_2024", "rucker_2023"]
    },
    "intranasal": {
      "onset": {
        "time": "rapid",
        "peakConcentration": {"min": 6, "max": 15.2, "unit": "minutes"}
      },
      "peak": {
        "time": {"min": 5, "max": 7, "unit": "minutes"}
      },
      "duration": {
        "time": {"value": 45, "unit": "minutes"}
      },
      "citations": ["engel_2024", "rucker_2023"]
    },
    "intravenous": {
      "onset": {
        "time": "almost immediate",
        "speed": "extremely_rapid"
      },
      "intensity": "extremely_high",
      "bioavailability": "complete",
      "riskLevel": "very_high",
      "citations": ["reckweg_2022"]
    },
    "intramuscular": {
      "onset": {
        "time": "slightly slower than IV",
        "speed": "rapid"
      },
      "intensity": "less than IV",
      "reactivationRisk": "lower than inhaled",
      "citations": ["barker_2022", "falchi-carvalho_2024", "ramaekers_2025"]
    },
    "oral": {
      "withoutMAOI": {
        "activity": "generally inactive",
        "reason": "Rapid breakdown by MAO enzymes in gut/liver",
        "citations": ["rafael_dos_santos_2024", "lowe_2022", "rucker_2024"]
      },
      "withMAOI": {
        "activity": "active",
        "riskLevel": "critical",
        "specificRisk": "Serotonin toxicity",
        "exposureIncrease": "Up to sixfold",
        "contraindicationType": "absolute_without_medical_supervision",
        "citations": ["malcolm_2022"]
      }
    },
    "sublingual": {
      "subjectiveIntensity": "lower",
      "dataAvailability": "limited",
      "citations": ["engel_2024"]
    },
    "rectal": {
      "dataAvailability": "limited",
      "citations": ["rucker_2024"]
    },
    "metabolism": {
      "primaryMetabolite": "bufotenine",
      "metaboliteActivity": "Yes - also psychoactive",
      "individualVariability": {
        "cytochromeP450": "Genetic polymorphisms affect metabolism",
        "implications": "Variable drug exposure and susceptibility to adverse effects",
        "citations": ["dourron_2023"]
      },
      "uncertainties": [
        "Unclear if bufotenine from metabolism produces notable effects",
        "Individual differences may influence bufotenine buildup",
        "Potential for unexpected effects from metabolite accumulation"
      ]
    }
  },

  "therapeuticApplications": {
    "investigationalUses": [
      {
        "condition": "treatment_resistant_depression",
        "status": "under_investigation",
        "evidence": "May reduce symptoms for at least one week",
        "evidenceQuality": "preliminary",
        "citations": ["dourron_2023"]
      }
    ],
    "patientReportedBenefits": [
      "PTSD symptom improvement",
      "Depression reduction",
      "Anxiety reduction",
      "Addiction support"
    ],
    "citations": ["davis_2018"]
  },

  "riskFactors": [
    {
      "id": "rf_5meo_potency_001",
      "name": "High Potency and Steep Dose-Response",
      "category": "pharmacological",
      "severity": "high",
      "description": "5-MeO-DMT is highly potent with steep dose-response curve",
      "implications": [
        "Small increases in dose cause large increases in effects",
        "Easy to accidentally overdose",
        "Difficult to control intensity",
        "Users often uncertain about dose consumed"
      ],
      "prevalence": "Many users uncertain of dose",
      "citations": ["lancelotta_2020", "bremler_2023"],
      "harmReduction": [
        "Precise measurement essential",
        "Start with lower doses",
        "Use volumetric dosing if possible",
        "Obtain from trusted sources with known potency"
      ]
    },
    {
      "id": "rf_5meo_intensity_001",
      "name": "Extreme Intensity of Experience",
      "category": "psychological",
      "severity": "high",
      "description": "Experiences often described as more intense than other psychedelics",
      "specificRisks": [
        "Overwhelming for unprepared users",
        "Challenging experiences",
        "Anxiety and fear",
        "Sense of dying or death"
      ],
      "firstTimeUsers": {
        "challengingEffects": 37,
        "unit": "percent",
        "citations": ["lancelotta_2020"]
      },
      "preparation": "Extra preparation crucial for managing intensity",
      "citations": ["dourron_2023", "lancelotta_2020"]
    },
    {
      "id": "rf_5meo_loss_control_001",
      "name": "Loss of Control and Unpredictable Behavior",
      "category": "behavioral",
      "severity": "moderate_to_high",
      "description": "Users may exhibit unexpected behaviors and lack awareness",
      "specificBehaviors": [
        "Vomiting",
        "Screaming",
        "Removing clothes",
        "Muscle jerking and twitching",
        "Abnormal vocalizations",
        "Self-injurious behavior (rare)",
        "Spontaneous orgasms",
        "Involuntary movements"
      ],
      "awareness": "Users often lack awareness or memory of behaviors during acute effects",
      "physicalDanger": "May pose physical danger due to involuntary movements",
      "citations": ["dourron_2023"],
      "requiredSupport": [
        "Experienced trip sitter essential",
        "Safe physical environment",
        "Monitoring throughout experience"
      ]
    },
    {
      "id": "rf_5meo_reactivations_001",
      "name": "Flashbacks/Reactivations",
      "category": "perceptual",
      "severity": "moderate_to_high",
      "description": "Brief re-experiences of drug effects after acute effects worn off",
      "prevalence": {
        "naturalistic": {
          "range": {"min": 27, "max": 73},
          "unit": "percent",
          "context": "Variable across studies",
          "citations": ["dourron_2023", "ortiz_bernal_2022"]
        },
        "clinical": {
          "value": 25,
          "unit": "percent",
          "context": "Treatment resistant depression participants",
          "distribution": "Across all dosing categories",
          "citations": ["dourron_2023"]
        },
        "structured_setting": {
          "value": 73,
          "unit": "percent",
          "context": "Users in structured ceremonial setting",
          "citations": ["dourron_2023"]
        },
        "general_population_sample": {
          "value": 27,
          "unit": "percent",
          "citations": ["dourron_2023"]
        }
      },
      "frequencyComparison": "More frequent with 5-MeO-DMT than typical psychedelics",
      "characteristics": {
        "duration": "Brief (seconds)",
        "components": "Visual, auditory, or emotional",
        "valence": "Most positive or neutral, some negative",
        "timing": "May be more common at night or when falling asleep",
        "spontaneity": "Spontaneous occurrence"
      },
      "negativeReactivations": {
        "ceremonialUsers": 4,
        "generalUsers": 7,
        "unit": "percent",
        "distress": "Some seek psychological help",
        "citations": ["dourron_2023"]
      },
      "routeAssociation": {
        "vaporized": "More likely to cause reactivations",
        "intramuscular": "Lower prevalence",
        "citations": ["dourron_2023", "ortiz_bernal_2022", "ramaekers_2025"]
      },
      "duration": {
        "typical": "Days to weeks",
        "prolonged": "Some anecdotal reports of months",
        "citations": ["ortiz_bernal_2022"]
      },
      "mechanism": {
        "hypothesis": "May relate to epileptiform activity in temporal lobes",
        "citations": ["dourron_2023"]
      },
      "requiredResearch": "Long-term follow-up needed to determine true frequency, intensity, duration, and impairment"
    },
    {
      "id": "rf_5meo_sensitization_001",
      "name": "Sensitization Rather Than Tolerance",
      "category": "pharmacological",
      "severity": "moderate",
      "description": "Repeated use may increase rather than decrease effects",
      "mechanism": "Opposite of tolerance - effects become stronger with repeated use",
      "evidence": [
        "Animal studies show behavioral sensitization",
        "May explain higher peak experiences with individualized dosing regimens"
      ],
      "implications": [
        "Unpredictable outcomes with repeated use",
        "Higher doses after previous exposure may be dangerous",
        "Different pattern from typical psychedelics"
      ],
      "citations": ["dourron_2003"],
      "harmReduction": "Caution with repeated use, don't assume tolerance"
    },
    {
      "id": "rf_5meo_seizure_risk_001",
      "name": "Potential for Seizure Activity",
      "category": "neurological",
      "severity": "moderate_to_high",
      "description": "Unique pharmacology may increase seizure risk",
      "mechanisms": [
        "White-outs may relate to seizure-like activity",
        "5-HT1A receptor action in medial temporal lobes",
        "May precipitate epileptiform activity"
      ],
      "manifestations": [
        "Muscle jerking",
        "Twitching",
        "Abnormal vocalizations",
        "Occasional self-injurious behavior",
        "Seizure-like behaviors"
      ],
      "evidence": [
        "Animal studies document seizure-like behaviors",
        "Some case reports in humans"
      ],
      "citations": ["dourron_2023"],
      "contraindication": "History of seizures or epilepsy"
    },
    {
      "id": "rf_5meo_metabolism_variability_001",
      "name": "Individual Metabolic Differences",
      "category": "pharmacogenetic",
      "severity": "moderate",
      "description": "Genetic variations affect 5-MeO-DMT metabolism",
      "specificFactors": [
        "Cytochrome P450 enzyme polymorphisms",
        "Variable drug exposure",
        "Different susceptibility to adverse effects",
        "Potential bufotenine accumulation"
      ],
      "implications": [
        "Unpredictable individual responses",
        "Some may experience unexpected effects from metabolites",
        "Difficult to predict safe dosing"
      ],
      "citations": ["dourron_2023"]
    },
    {
      "id": "rf_5meo_maoi_interaction_001",
      "name": "Dangerous MAOI Interactions",
      "category": "drug_interaction",
      "severity": "critical",
      "description": "Combining with MAOIs can be fatal",
      "mechanism": [
        "MAOIs inhibit breakdown of 5-MeO-DMT",
        "Increases exposure up to sixfold",
        "Can lead to fatal serotonin syndrome"
      ],
      "specificCombinations": [
        {
          "substance": "harmala_alkaloids",
          "found_in": "ayahuasca, Syrian rue",
          "examples": ["harmine", "harmaline", "tetrahydroharmine"],
          "exposureIncrease": "Up to sixfold",
          "outcome": "Fatal serotonin toxicity documented",
          "citations": ["malcolm_2022"]
        },
        {
          "substance": "pharmaceutical_MAOIs",
          "examples": ["moclobemide", "phenelzine", "tranylcypromine"],
          "outcome": "Severe to fatal serotonin syndrome"
        },
        {
          "substance": "other_tryptamines",
          "outcome": "Serotonin toxicity and death when combined with harmala alkaloids",
          "citations": ["malcolm_2022"]
        }
      ],
      "contraindicationType": "absolute",
      "deathsReported": true,
      "note": "Safety profile with MAOIs different from classical tryptamines",
      "citations": ["malcolm_2022"]
    },
    {
      "id": "rf_5meo_source_variability_001",
      "name": "Source-Related Variability",
      "category": "quality",
      "severity": "high",
      "description": "Different experiences based on toad-derived vs synthetic source",
      "toadDerived": {
        "variability": "Significant concentration variability",
        "additionalCompounds": [
          "bufotenine",
          "other_bufotoxins"
        ],
        "uncertainEffects": "Unclear if bufotenine in venom significantly impacts effects",
        "dosing": "Inconsistent and dangerous",
        "ethical": "Animal welfare concerns",
        "citations": ["neumann_2024", "dourron_2023"]
      },
      "synthetic": {
        "advantages": ["Consistent potency", "No bufotenine", "No animal harm"],
        "risks": ["Synthesis impurities", "Potential mislabeling", "Adulteration"]
      },
      "userReports": "Differences in reported experiences between toad and synthetic",
      "citations": ["ortiz_bernal_2022", "dourron_2023"]
    }
  ],

  "contraindications": {
    "absolute": [
      {
        "id": "contra_5meo_maoi_001",
        "condition": "Concurrent use of MAOIs",
        "severity": "critical",
        "rationale": "Fatal serotonin syndrome risk",
        "includes": [
          "Pharmaceutical MAOIs",
          "Reversible MAOIs (moclobemide)",
          "Harmala alkaloids (ayahuasca, Syrian rue)",
          "Natural MAOIs"
        ],
        "outcome": "Potentially fatal",
        "evidenceQuality": "strong",
        "citations": ["malcolm_2022"]
      },
      {
        "id": "contra_5meo_psychosis_001",
        "condition": "Personal history of psychotic disorders",
        "severity": "high",
        "includes": [
          "Schizophrenia",
          "Schizophreniform disorders",
          "Psychotic depression",
          "Active mania"
        ],
        "rationale": "Risk of long-lasting psychotic reactions",
        "citations": ["sabe_2024", "white_2024"]
      },
      {
        "id": "contra_5meo_family_psychosis_001",
        "condition": "Family history of psychotic disorders",
        "severity": "high",
        "includes": [
          "First or second-degree relatives with schizophrenia",
          "Family history of bipolar disorder with psychosis"
        ],
        "rationale": "Elevated risk of adverse reactions",
        "citations": ["sabe_2024", "white_2024"]
      }
    ],
    "relative": [
      {
        "id": "contra_5meo_cardiovascular_001",
        "condition": "Cardiovascular conditions",
        "severity": "moderate_to_high",
        "rationale": "Effects on cardiovascular system not well understood",
        "specificRisks": [
          "Strong G-protein binding activation",
          "Dose-dependent blood pressure increases",
          "Dose-dependent heart rate increases"
        ],
        "requiredAssessment": "Careful medical evaluation and monitoring",
        "citations": ["malcolm_2022", "james_2024"]
      },
      {
        "id": "contra_5meo_psych_vulnerabilities_001",
        "condition": "Prior psychological vulnerabilities",
        "severity": "moderate",
        "includes": [
          "History of anxiety",
          "History of depression",
          "Trauma history"
        ],
        "specificRisk": "87% experienced worsening anxiety in one study",
        "requiredPrecautions": [
          "Careful screening",
          "Enhanced preparation",
          "Increased support"
        ],
        "citations": ["bremler_2023"]
      },
      {
        "id": "contra_5meo_uncontrolled_setting_001",
        "condition": "Uncontrolled settings",
        "severity": "high",
        "rationale": "Unpredictable nature makes it less safe without controls",
        "requiredFactors": [
          "Proper dose control",
          "Appropriate setting",
          "Mindset management",
          "Professional or experienced support"
        ],
        "citations": ["bremler_2023"]
      },
      {
        "id": "contra_5meo_recreational_001",
        "condition": "Recreational use",
        "severity": "moderate_to_high",
        "rationale": "Lacks safety measures of clinical or ceremonial settings",
        "risks": [
          "Dosage uncertainty",
          "Adulterants",
          "Lack of support",
          "Inappropriate setting"
        ],
        "citations": ["gomez-escolar_2024"]
      },
      {
        "id": "contra_5meo_polydrug_001",
        "condition": "Mixing with other substances",
        "severity": "high",
        "specificallyDangerous": [
          "Other serotonergic substances",
          "Stimulants",
          "Alcohol"
        ],
        "outcome": "Increased risk of serotonin toxicity and other adverse events",
        "citations": ["malcolm_2022", "barnett_2021"]
      }
    ]
  },

  "adverseEvents": {
    "acute": {
      "psychological": [
        {
          "id": "ae_5meo_anxiety_001",
          "name": "Anxiety and Fear",
          "severity": "mild_to_severe",
          "prevalence": "common",
          "timing": "Particularly prior to and during onset (first 10-15 minutes)",
          "characteristics": [
            "Can be intense",
            "Often subsides as experience progresses",
            "More common in unprepared users"
          ],
          "citations": ["ramaekers_2025", "rucker_2024", "kwasny_2024"]
        },
        {
          "id": "ae_5meo_distress_001",
          "name": "Psychological Distress",
          "severity": "variable",
          "description": "Challenging emotions during experience",
          "note": "While some experiences are cathartic, they can be psychologically distressing",
          "citations": ["ramaekers_2025"]
        },
        {
          "id": "ae_5meo_confusion_001",
          "name": "Confusional States",
          "severity": "moderate",
          "prevalence": "reported in studies",
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_hallucinations_001",
          "name": "Hallucinations",
          "severity": "variable",
          "prevalence": "reported",
          "specificity": "Nature not always detailed",
          "citations": ["kwasny_2024", "dourron_2023"]
        },
        {
          "id": "ae_5meo_depression_acute_001",
          "name": "Depressive Symptoms",
          "severity": "mild_to_moderate",
          "timing": "acute phase",
          "prevalence": "Some cases reported",
          "citations": ["kwasny_2024"]
        },
        {
          "id": "ae_5meo_ego_dissolution_001",
          "name": "Ego Dissolution",
          "severity": "profound",
          "valence": "Can be positive or distressing",
          "description": "Strong sense of ego dissolution, detachment from body, altered self-perception",
          "citations": ["falchi-carvalho_2024", "dourron_2023"]
        },
        {
          "id": "ae_5meo_mystical_overwhelming_001",
          "name": "Overwhelming Mystical Experiences",
          "severity": "profound",
          "valence": "Often positive but can be challenging",
          "characteristics": [
            "Awe",
            "Amazement",
            "Loss of time and space",
            "Ineffability"
          ],
          "intensity": "Can be overwhelming for some",
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_whiteout_001",
          "name": "White-out Experiences",
          "severity": "profound",
          "description": "Loss of awareness, void experience",
          "characteristics": [
            "Disorienting",
            "Loss of control",
            "Amnesia for parts of experience"
          ],
          "citations": ["dourron_2023"]
        }
      ],
      "physiological": [
        {
          "id": "ae_5meo_cardiovascular_001",
          "name": "Cardiovascular Changes",
          "severity": "mild_to_moderate",
          "manifestations": [
            {
              "effect": "increased_blood_pressure",
              "severity": "transient",
              "duration": "during_experience"
            },
            {
              "effect": "increased_heart_rate",
              "severity": "transient",
              "duration": "during_experience"
            }
          ],
          "citations": ["ramaekers_2025", "white_2024", "rucker_2023", "kwasny_2024", "falchi-carvalho_2024"]
        },
        {
          "id": "ae_5meo_nausea_001",
          "name": "Gastrointestinal Effects",
          "severity": "mild_to_moderate",
          "manifestations": [
            "nausea",
            "headache",
            "vomiting"
          ],
          "frequency": "common",
          "citations": ["ramaekers_2025", "rucker_2024", "white_2024"]
        },
        {
          "id": "ae_5meo_nasal_discomfort_001",
          "name": "Nasal Discomfort",
          "severity": "mild",
          "route": "intranasal administration",
          "frequency": "common",
          "citations": ["rucker_2024"]
        },
        {
          "id": "ae_5meo_muscle_001",
          "name": "Muscle Effects",
          "severity": "mild_to_moderate",
          "manifestations": [
            "muscle_spasms",
            "muscle_discomfort"
          ],
          "citations": ["kwasny_2024"]
        },
        {
          "id": "ae_5meo_serotonin_syndrome_001",
          "name": "Serotonin Toxicity",
          "severity": "critical",
          "description": "Life-threatening serotonin syndrome",
          "triggers": [
            "Combination with MAOIs",
            "Combination with harmala alkaloids"
          ],
          "mechanism": "Excessive serotonin accumulation",
          "outcome": "Can be fatal",
          "prevention": "Absolute contraindication for MAOI combinations",
          "citations": ["malcolm_2022"]
        },
        {
          "id": "ae_5meo_sensory_001",
          "name": "Sensory Disturbances",
          "severity": "mild_to_moderate",
          "manifestations": [
            {
              "symptom": "hyperacusis",
              "description": "Increased sensitivity to sound"
            },
            {
              "symptom": "blurred_vision"
            }
          ],
          "citations": ["kwasny_2024"]
        },
        {
          "id": "ae_5meo_temperature_001",
          "name": "Temperature Dysregulation",
          "severity": "mild",
          "manifestations": [
            "feeling_hot",
            "discomfort"
          ],
          "citations": ["kwasny_2024"]
        },
        {
          "id": "ae_5meo_fatigue_001",
          "name": "Fatigue",
          "severity": "mild",
          "timing": "Often following peak experience",
          "citations": ["kwasny_2024"]
        },
        {
          "id": "ae_5meo_clumsiness_001",
          "name": "Clumsiness",
          "severity": "mild",
          "timing": "During acute effects",
          "citations": ["kwasny_2024"]
        }
      ],
      "behavioral": [
        {
          "id": "ae_5meo_loss_control_001",
          "name": "Loss of Behavioral Control",
          "severity": "moderate_to_high",
          "manifestations": [
            "unusual_movements",
            "twitching",
            "abnormal_vocalizations"
          ],
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_unpredictable_behavior_001",
          "name": "Unpredictable Behaviors",
          "severity": "moderate",
          "examples": [
            "vomiting",
            "screaming",
            "removing_clothes"
          ],
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_self_injury_001",
          "name": "Self-Injurious Behavior",
          "severity": "high",
          "frequency": "rare",
          "description": "Anecdotal reports of self-harm",
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_involuntary_movement_001",
          "name": "Involuntary Movements",
          "severity": "moderate",
          "description": "Involuntary bodily movements, seizure-like behaviors",
          "citations": ["dourron_2003"]
        },
        {
          "id": "ae_5meo_lack_awareness_001",
          "name": "Lack of Awareness",
          "severity": "moderate_to_high",
          "description": "Users may lack awareness or memory of behaviors during acute effects",
          "riskImplication": "Cannot monitor own safety",
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_hypersexual_001",
          "name": "Hypersexual Experiences",
          "severity": "variable",
          "manifestations": [
            "Highly sensual experiences",
            "Spontaneous orgasms"
          ],
          "frequency": "Anecdotally reported",
          "citations": ["dourron_2023"]
        }
      ],
      "clinicalTrialSafety": {
        "seriousAdverseEvents": {
          "prevalence": "None reported",
          "context": "Controlled clinical trials",
          "citations": ["rucker_2023", "hinkle_2024", "kwasny_2024"]
        },
        "withdrawal": {
          "prevalence": "No adverse events led to participant withdrawal",
          "citations": ["kwasny_2024"]
        },
        "mostFrequentIntranasal": [
          "nasal_discomfort",
          "nausea",
          "headache",
          "vomiting"
        ],
        "vitalSigns": {
          "observation": "No clinically relevant changes",
          "monitoring": ["vital_signs", "ECG", "telemetry", "laboratory_safety_tests"]
        },
        "nasalMucosa": {
          "observation": "No observed effects"
        },
        "citations": ["rucker_2023"]
      },
      "firstTimeUserData": {
        "challengingEffects": {
          "prevalence": 37,
          "unit": "percent",
          "effects": [
            "heart_beating",
            "fear",
            "body_shaking",
            "anxiety",
            "feeling_like_dying",
            "pressure_on_chest",
            "panic"
          ],
          "citations": ["lancelotta_2020"]
        }
      }
    },
    "longTerm": {
      "psychological": [
        {
          "id": "ae_5meo_reactivations_lt_001",
          "name": "Flashbacks/Reactivations",
          "severity": "variable",
          "description": "Spontaneous re-experiencing of drug effects",
          "prevalence": {
            "naturalistic": {
              "structured_setting": 73,
              "general_sample": 27,
              "unit": "percent"
            },
            "clinical": {
              "value": 25,
              "unit": "percent",
              "context": "Treatment resistant depression study",
              "distribution": "Across all dosing categories"
            }
          },
          "characteristics": {
            "duration": "Brief (seconds)",
            "components": ["Visual", "Emotional", "Cognitive"],
            "timing": "May be more common at night/falling asleep",
            "spontaneity": true
          },
          "valence": {
            "mostCommon": "Positive or neutral",
            "negative": {
              "ceremonial": 4,
              "naturalistic": 7,
              "unit": "percent"
            }
          },
          "distress": {
            "someSeekHelp": true,
            "comparisonToClassical": "Higher rate than LSD/psilocybin (1.4%)"
          },
          "typicalResolution": "Days to weeks",
          "prolongedCases": "Some anecdotal reports of months",
          "routeAssociation": {
            "vaporized": "More likely",
            "intramuscular": "Lower prevalence"
          },
          "mechanism": {
            "hypothesis": "May relate to epileptiform activity",
            "location": "Temporal lobes"
          },
          "citations": ["ortiz_bernal_2022", "dourron_2023", "ramaekers_2025"],
          "researchNeeded": "Long-term follow-up to determine frequency, intensity, duration, impairment"
        },
        {
          "id": "ae_5meo_hppd_lt_001",
          "name": "Hallucinogen Persisting Perception Disorder (HPPD)",
          "severity": "variable",
          "evidence": "Not explicitly linked in same way as other psychedelics",
          "type1": {
            "description": "Short term, reversible, benign",
            "comparison": "Reactivations may be similar to Type 1 HPPD"
          },
          "type2": {
            "description": "More severe and long-term",
            "documentation": "No studies documenting HPPD specifically from 5-MeO-DMT"
          },
          "symptoms": [
            "Visual disturbances (flashes, intensified colors, palinopsia)",
            "False perceptions of movement",
            "Recurrent synesthesia",
            "Dissociation",
            "Depersonalization"
          ],
          "note": "Theoretical risk based on other psychedelics",
          "citations": ["ramaekers_2024", "scala_2024", "ortiz_bernal_2022"]
        },
        {
          "id": "ae_5meo_sensitization_lt_001",
          "name": "Sensitization with Repeated Use",
          "severity": "moderate",
          "description": "Effects may become stronger rather than weaker with repeated use",
          "mechanism": "Opposite of tolerance",
          "evidence": [
            "Animal studies show behavioral sensitization",
            "Individualized dosing regimens show higher peak experiences"
          ],
          "implication": "Users may become more sensitive after repeated use",
          "citations": ["dourron_2023"]
        },
        {
          "id": "ae_5meo_memory_lt_001",
          "name": "Memory Impairment",
          "severity": "unknown",
          "evidence": "Transient impairment documented with psychedelics generally",
          "specificTo5MeO": "No specific indication of long-term memory impairment",
          "citations": ["kuypers_2005"]
        },
        {
          "id": "ae_5meo_addiction_lt_001",
          "name": "Addiction Potential",
          "severity": "low",
          "evidence": "Similar to classic psychedelics",
          "lifetimeUse": "Rare",
          "note": "While compulsive use risk is low, some may repeatedly use despite undesirable experiences",
          "citations": ["kwasny_2024", "dourron_2023"]
        },
        {
          "id": "ae_5meo_negative_emotions_lt_001",
          "name": "Persistent Negative Emotional States",
          "severity": "moderate",
          "duration": "Can persist months",
          "prevalence": "Some cases",
          "clinicalSignificance": "May lead to clinically significant problems",
          "citations": ["dourron_2023", "ortiz_bernal_2022"]
        },
        {
          "id": "ae_5meo_psychiatric_dx_lt_001",
          "name": "Emergence of Psychiatric Diagnoses",
          "severity": "moderate_to_high",
          "prevalence": {
            "value": 37.5,
            "unit": "percent",
            "context": "Study of negative psychological responses to psychedelics",
            "note": "Diagnosis emerged after psychedelic experience"
          },
          "anxietyWorsening": {
            "value": 87,
            "unit": "percent",
            "context": "Anxiety symptoms arose or worsened"
          },
          "uncertainties": [
            "Causal relationship unclear",
            "Pre-existing vulnerabilities may be factor"
          ],
          "citations": ["bremler_2023"]
        },
        {
          "id": "ae_5meo_professional_help_lt_001",
          "name": "Need for Professional Assistance",
          "severity": "variable",
          "prevalence": {
            "ayahuasca": {
              "value": 12,
              "unit": "percent",
              "context": "Ayahuasca users seeking mental health assistance"
            }
          },
          "note": "Specific data for 5-MeO-DMT not provided but likely similar",
          "citations": ["evans_2023", "robinson_2024"]
        }
      ],
      "evidenceLimitations": [
        "Limited long-term follow-up studies",
        "Most data from naturalistic use",
        "Clinical trials are short-term",
        "Underreporting likely"
      ]
    }
  },

  "qualityContaminationRisks": [
    {
      "id": "quality_5meo_dosing_uncertainty_001",
      "name": "Dosing Uncertainty",
      "category": "quality",
      "severity": "high",
      "description": "Lack of standardization leads to uncertain dosing",
      "factors": [
        "No regulatory oversight",
        "Dose varies significantly in products",
        "Users cannot gauge amount consumed",
        "Steep dose-response increases risk"
      ],
      "citations": ["lancelotta_2020"]
    },
    {
      "id": "quality_5meo_purity_variability_001",
      "name": "Purity Variability",
      "category": "quality",
      "severity": "high",
      "description": "Inconsistent purity leads to unpredictable effects",
      "factors": [
        "Unregulated markets",
        "Variable extraction processes",
        "Storage conditions affect potency",
        "Difficult to determine safe dose"
      ],
      "citations": ["glynos_2023", "edwards_2023", "coyle_nd"]
    },
    {
      "id": "quality_5meo_toad_variability_001",
      "name": "Toad-Derived Variability",
      "category": "source",
      "severity": "high",
      "description": "Venom from Incilius alvarius varies significantly",
      "specificFactors": [
        {
          "factor": "variable_concentrations",
          "description": "5-MeO-DMT concentration varies in toad venom",
          "implication": "Inconsistent and dangerous dosing",
          "citations": ["neumann_2024"]
        },
        {
          "factor": "bufotenine_presence",
          "description": "Bufotenine also present in venom",
          "psychoactivity": "Also has psychoactive properties",
          "adverseEffects": "Can cause adverse effects",
          "uncertainty": "Unclear if bufotenine from venom significantly impacts effects vs. from 5-MeO-DMT metabolism",
          "citations": ["dourron_2023"]
        },
        {
          "factor": "other_compounds",
          "description": "Multiple compounds in toad venom beyond 5-MeO-DMT and bufotenine"
        }
      ],
      "ethicalConcerns": [
        "Ethical treatment of toads",
        "Environmental impact on toad populations"
      ]
    },
    {
      "id": "quality_5meo_synthetic_risks_001",
      "name": "Synthetic Production Risks",
      "category": "source",
      "severity": "moderate",
      "description": "Risks associated with synthetic 5-MeO-DMT",
      "risks": [
        {
          "risk": "synthesis_impurities",
          "description": "Byproducts and impurities if synthesis not done properly",
          "citations": ["bremler_2023"]
        },
        {
          "risk": "adulteration",
          "description": "Intentional adulteration with other substances"
        },
        {
          "risk": "mislabeling",
          "description": "Synthetic versions may be misrepresented",
          "consequence": "Users unknowingly consume different substance",
          "citations": ["bremler_2023"]
        }
      ],
      "advantages": [
        "More consistent potency than toad-derived",
        "No animal harm",
        "No bufotenine (unless intentionally added)"
      ]
    },
    {
      "id": "quality_5meo_potency_inconsistency_001",
      "name": "Potency Inconsistencies Within Batches",
      "category": "quality",
      "severity": "high",
      "description": "Even within single batch, potency can vary",
      "implication": "Unintentionally consuming much higher dose than intended",
      "riskFactor": "Accidental overdose",
      "commonAdulterants": "More potent adulterants increase risk",
      "citations": ["petranker_2022", "hirschfeld_2021", "palamar_2020"]
    },
    {
      "id": "quality_5meo_misidentification_001",
      "name": "Substance Misidentification",
      "category": "contamination",
      "severity": "critical",
      "description": "Substances sold as 5-MeO-DMT may not contain it",
      "examples": [
        {
          "soldAs": "5-MeO-DMT",
          "actualContent": "Other synthetic tryptamines",
          "similarSubstances": ["5-MeO-AMT"],
          "knownIssues": "Sold as LSD, responsible for emergency cases",
          "citations": ["calina_2021"]
        }
      ],
      "consequences": [
        "Unexpected effects",
        "Potentially harmful effects",
        "Unknown toxicological profiles"
      ],
      "citations": ["hirschfeld_2021", "petranker_2022", "coyle_nd", "bremler_2023", "calina_2021"]
    },
    {
      "id": "quality_5meo_adulterants_001",
      "name": "Adulteration with Unknown Substances",
      "category": "contamination",
      "severity": "high",
      "description": "Presence of other psychoactive substances",
      "risks": [
        "Unpredictable effects",
        "Different safety profiles",
        "More dangerous than 5-MeO-DMT alone"
      ],
      "citations": ["glynos_2023", "hirschfeld_2021", "petranker_2022", "strassman_1984"]
    },
    {
      "id": "quality_5meo_manufacturing_contamination_001",
      "name": "Manufacturing Byproducts",
      "category": "contamination",
      "severity": "moderate",
      "description": "Inadequate cleaning of production equipment in illicit labs",
      "consequences": [
        "Byproducts in final product",
        "Impurities from previous batches",
        "Cross-contamination"
      ],
      "citations": ["aakerøy_2021"]
    },
    {
      "id": "quality_5meo_unintended_substances_001",
      "name": "Cross-Contamination",
      "category": "contamination",
      "severity": "moderate_to_high",
      "description": "Unintended substances from production process",
      "citations": ["hirschfeld_2021", "petranker_2022", "coyle_nd", "aakerøy_2021", "strassman_1984"]
    },
    {
      "id": "quality_5meo_serotonergic_contamination_001",
      "name": "Contamination with Serotonergic Agents",
      "category": "contamination",
      "severity": "critical",
      "description": "Combination of 5-MeO-DMT with other serotonergic substances",
      "outcome": "Serotonin toxicity (serotonin syndrome)",
      "severity": "Potentially life-threatening",
      "citations": ["malcolm_2022"]
    },
    {
      "id": "quality_5meo_research_chemicals_001",
      "name": "Research Chemical Misrepresentation",
      "category": "sourcing",
      "severity": "high",
      "description": "Substances sold as 'research chemicals' may be misrepresented",
      "risks": [
        "Unknown compounds",
        "Byproducts and contaminants",
        "No quality control"
      ],
      "citations": ["coyle_nd"]
    },
    {
      "id": "quality_5meo_longterm_health_001",
      "name": "Long-term Health Risks from Contaminants",
      "category": "health",
      "severity": "unknown",
      "description": "Chronic exposure to contaminants or impure 5-MeO-DMT",
      "evidence": "Not well understood due to lack of data",
      "citations": ["hirschfeld_2021", "ghaznavi_2025"]
    },
    {
      "id": "quality_5meo_testing_limitations_001",
      "name": "Lack of Accurate Testing",
      "category": "harm_reduction",
      "severity": "high",
      "description": "Limited access to accurate testing methods",
      "issues": [
        "Drug test kits often unreliable",
        "Cannot detect all adulterants",
        "Cannot accurately measure amount",
        "Cannot predict individual response"
      ],
      "citations": ["glynos_2023", "petranker_2022"]
    }
  ],

  "harmReductionStrategies": [
    {
      "id": "hr_5meo_screening_001",
      "category": "preparation",
      "strategy": "Comprehensive Medical and Psychiatric Screening",
      "importance": "critical",
      "components": [
        "Personal and family psychiatric history",
        "Cardiovascular assessment",
        "Medication review (especially MAOIs)",
        "Substance use history",
        "Seizure history"
      ],
      "effectiveness": "high"
    },
    {
      "id": "hr_5meo_experienced_sitter_001",
      "category": "supervision",
      "strategy": "Experienced Trip Sitter",
      "importance": "critical",
      "rationale": "Intense physical and psychological reactions require experienced support",
      "qualifications": [
        "Relevant experience with 5-MeO-DMT",
        "Ability to manage challenging experiences",
        "Knowledge of when to seek emergency help"
      ],
      "citations": ["engel_2022"]
    },
    {
      "id": "hr_5meo_dose_control_001",
      "category": "dosing",
      "strategy": "Precise Dose Measurement",
      "importance": "critical",
      "methods": [
        "Volumetric dosing when possible",
        "Accurate scales (0.001g precision)",
        "Starting with lower doses",
        "Avoiding dose escalation without proper spacing"
      ],
      "rationale": "Steep dose-response curve makes precision essential"
    },
    {
      "id": "hr_5meo_substance_testing_001",
      "category": "quality_control",
      "strategy": "Substance Testing",
      "importance": "high",
      "methods": [
        "Reagent test kits",
        "Drug checking services if available",
        "Testing new batches"
      ],
      "limitations": [
        "Cannot detect all adulterants",
        "Cannot measure exact potency",
        "Limited availability"
      ]
    },
    {
      "id": "hr_5meo_trusted_sources_001",
      "category": "sourcing",
      "strategy": "Obtain from Trusted Sources",
      "importance": "high",
      "rationale": "Reduces risk of adulteration and unknown substances",
      "preferSynthetic": "Generally more consistent than toad-derived",
      "citations": ["lancelotta_2020"]
    },
    {
      "id": "hr_5meo_maoi_avoidance_001",
      "category": "drug_interactions",
      "strategy": "Absolute Avoidance of MAOIs",
      "importance": "critical",
      "timeframe": "At least 2 weeks before and after 5-MeO-DMT use",
      "includes": [
        "Pharmaceutical MAOIs",
        "Harmala alkaloids",
        "Syrian rue",
        "Ayahuasca",
        "Natural MAOIs"
      ],
      "rationale": "Fatal serotonin syndrome risk"
    },
    {
      "id": "hr_5meo_polydrug_avoidance_001",
      "category": "drug_interactions",
      "strategy": "Avoid Polydrug Use",
      "importance": "high",
      "specificallyAvoid": [
        "Other serotonergic substances",
        "Stimulants",
        "Alcohol",
        "Other psychedelics"
      ]
    },
    {
      "id": "hr_5meo_setting_001",
      "category": "environment",
      "strategy": "Safe, Controlled Setting",
      "importance": "high",
      "characteristics": [
        "Comfortable, secure environment",
        "Free from hazards",
        "Private",
        "Supportive",
        "Temperature controlled"
      ]
    },
    {
      "id": "hr_5meo_preparation_001",
      "category": "psychological",
      "strategy": "Thorough Psychological Preparation",
      "importance": "high",
      "components": [
        "Education about effects",
        "Intention setting",
        "Anxiety management techniques",
        "Surrender and acceptance practice",
        "Understanding of potential intensity"
      ]
    },
    {
      "id": "hr_5meo_route_selection_001",
      "category": "administration",
      "strategy": "Careful Route Selection",
      "importance": "moderate_to_high",
      "considerations": [
        "Intranasal or IM may have lower reactivation risk than vaporized",
        "IV route has highest intensity and risk",
        "Sublingual has lower intensity",
        "Never combine with MAOIs for oral route"
      ]
    },
    {
      "id": "hr_5meo_integration_001",
      "category": "post_experience",
      "strategy": "Integration Support",
      "importance": "high",
      "components": [
        "Processing experience with therapist or guide",
        "Peer support groups",
        "Journaling",
        "Time for reflection",
        "Addressing reactivations if they occur"
      ]
    },
    {
      "id": "hr_5meo_emergency_access_001",
      "category": "safety",
      "strategy": "Access to Emergency Support",
      "importance": "critical",
      "resources": [
        "Psychedelic crisis helplines (e.g., Fireside Project)",
        "Emergency medical services contact information",
        "Benzodiazepines available if in clinical setting"
      ]
    },
    {
      "id": "hr_5meo_repeat_use_caution_001",
      "category": "use_patterns",
      "strategy": "Caution with Repeated Use",
      "importance": "moderate",
      "rationale": "Sensitization may occur rather than tolerance",
      "recommendation": "Do not assume tolerance; may need lower doses with repeated use"
    }
  ],

  "emergencyProtocols": {
    "nonPharmacological": [
      {
        "intervention": "reassurance",
        "description": "Verbal reassurance that experience is temporary and they are safe",
        "effectiveness": "Usually sufficient for psychological distress"
      },
      {
        "intervention": "calm_presence",
        "description": "Sitter maintains calm, grounded demeanor"
      },
      {
        "intervention": "environmental_adjustment",
        "description": "Quiet, dimly lit, comfortable environment"
      },
      {
        "intervention": "breathing_guidance",
        "description": "Guide slow, deep breathing"
      },
      {
        "intervention": "physical_safety",
        "description": "Prevent injury from involuntary movements"
      }
    ],
    "pharmacological": [
      {
        "medication": "benzodiazepines",
        "indication": "Severe anxiety or agitation unresponsive to reassurance",
        "note": "Should be available in clinical settings"
      }
    ],
    "emergencyServices": {
      "when": [
        "Seizure activity",
        "Cardiovascular emergency",
        "Suspected serotonin syndrome",
        "Severe behavioral disturbance",
        "Self-harm risk",
        "Condition not improving"
      ]
    }
  },

  "researchNeeds": [
    "Long-term safety studies",
    "Systematic dose-finding studies in humans",
    "Standardized protocols for different routes",
    "Better understanding of reactivations/flashbacks",
    "Mechanism of sensitization",
    "Optimal integration practices",
    "Cardiovascular safety in at-risk populations",
    "Comparison of toad-derived vs synthetic preparations",
    "Pharmacogenetic studies",
    "Larger diverse population studies"
  ],

  "metadata": {
    "substanceSpecificCitations": 150,
    "primaryDataSources": [
      "Clinical trials (limited)",
      "Observational studies",
      "Surveys of naturalistic users",
      "Case reports",
      "Animal studies"
    ],
    "dataQuality": "Limited compared to classical psychedelics",
    "geographicScope": "Primarily North American data",
    "keyLimitations": [
      "Limited human dosing studies",
      "Most data from naturalistic use",
      "Small sample sizes in clinical research",
      "Lack of long-term follow-up",
      "Source variability (toad vs synthetic) confounds data",
      "Underreporting likely",
      "Limited diversity in studied populations"
    ],
    "majorKnowledgeGaps": [
      "Optimal therapeutic dosing",
      "Long-term effects",
      "True prevalence of reactivations",
      "Mechanisms of unique effects",
      "Cardiovascular safety profile",
      "Comparison to classical psychedelics in therapeutic settings"
    ]
  }
}